WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Transplant Product Efficacy Framework v11a, Banff grade is staged as IIB, Transplant Donor has accumulated Medical History (Donor), Transplant Recipient has accumulated Medical History (Recipient), Estimated GFR (eGFR) accounts for Serum Creatinine (SCr), defined time points including 12 months, Medical History (Recipient) contains Urine Output, Medical History (Recipient) contains Dialysis Prior to Transplant, Banff grade is staged as IIA, Diagnosis includes Diabetes, Approved Concomitant Anti-rejection therapy has (1..n) Drug Name, EBV increases risk for PTLD (post-transplant lymphoproliferative disorder), Study Drug | Comparator taken in combination with Induction Agent, Study Drug | Comparator has value for Dosage, Glomerular Filtration Rate (GFR) is associated with Cardiovascular (CV) risk, Chronic includes Mild, Medical History (Recipient) contains BMI, Transplant Donor has donor type Living-non-related, Transplant Donor has HLA types, Estimated GFR (eGFR) is correlated with Graft Loss, CV death can result from Toxicity